Recipharm Inhalation Solutions™
Product Description
Recipharm
-
SE -
2015On CPHI since
-
5000+Employees
Company types
Categories
Recipharm
-
SE
-
2015On CPHI since
-
5000+Employees
Company types
More Products from Recipharm (21)
-
Product Drug Substance
Recipharm has more than 25 years’ experience in drug substance development and manufacturing. We are ideally placed to deliver a wide range of drug substance services from our dedicated development facilities around the world. -
Product Serialisation
Recipharm have committed to invest in and fully implement the technical solutions needed to comply with global requirements for pharmaceutical serialisation and track and trace. Our serialisation offering includes: • Experience in already providing serialised products to Turkey, Korea and China • Se... -
Product Clinical Supply
Recipharm have more than 20 years experience supplying clinical trial material to our clients. Our development facilities cater for a range of clinical trials from preclincal to smaller Phase III trials. We also offer commercial manufacturing for very large clinical batches. -
Product APIs
Recipharm operate facilities which can manufacture several products at a time, handling high pressure, high temperature (up to 150 degrees Celsius) and low temperature (down to –80 degrees Celsius) reactions. Different batch sizes are available ranging from 20L to 6000L, supporting early development and co... -
Product Analytical Development
Recipharm offer analytical support for drug discovery, pharmaceutical development and manufacturing through our global development facilities. -
Product Synthetic Chemistry
Recipharm offer a range of synthetic chemistry services through our global development facilities including advanced lead optimisation medicinal chemistry, process development and tech transfer to large scale GMP-manufacturing and other specialties. -
Product Recipharm Analytical Solutions™
Through Recipharm Analytical Solutions™, we support customers with stand-alone analytical requirements. Our analytical development team has experience from developing hundreds of analytical methods every year, supporting development of formulations ranging from powder in capsules and IV solutions to ER tab... -
Product Injectables
Recipharm has extensive experience in the injectables area and supplies small volume parenterals in ampoules and vials, as well as in cartridges. State of the art leak detection and automatic inspection equipment is used and Recipharm’s full service offering is complete with secondary packaging and tempera... -
Product Ophthalmics
Recipharm offers pharmaceutical contract development and manufacturing in ophthalmics including, sterile manufacturing of eye and ear drops in plastic multi-dose containers and blow-fill-seal technology for single and as multi-dose use. -
Product Liquids
Recipharm offers pharmaceutical contract development and manufacturing of liquids, sprays and aerosols, with a broad range of equipment and compounding vessels from 100L to 5000L. -
Product Semi-solids
Recipharm offers pharmaceutical contract development and manufacturing of semi-solids including, APIs, creams, emulsions, gels, ointments, aerosols and suppositories. We have the capability to fill products in aluminum tubes, plastic tubes, syringes, aluminum cans, PVC or aluminum blist... -
Product Solids
Recipharm offers pharmaceutical contract development and manufacturing of large commercial batch sizes of tablets, capsules or powders.
Recipharm work with: • General APIs as well as some special substances • Conventional technologies, including fluid...
Recipharm resources (10)
-
News Sustainability in pharmaceutical manufacturing: an expert panel discussion
In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. -
Brochure Recipharm's full service offering
Your innovative drug. Our world-class production facilities. Discover the genius of working together. -
News Recipharm receives approval for the manufacture of a new microbiome-based therapeutic
Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics. -
News Watch now: Pharma Trends 2022 Webinar
We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event. -
News Lyophilisation technology improving thermal stability and reducing cycle times, says Recipharm expert
Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.
-
Sponsored Content Key considerations to develop effective analytical methods for your drug project
A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects. -
News CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task. -
News Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. -
Sponsored Content CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples. -
Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance